文献速递肝病

血清抗核抗体阳性不影响非酒精性脂肪性肝病的长期结局

Presence of Serum Antinuclear Antibodies Does Not Impact Long-Term Outcomes in Nonalcoholic Fatty Liver Disease.
PubMed 文献 · Am J Gastroenterol · 2020-01-01

该研究纳入923例经活检证实的非酒精性脂肪性肝病患者,其中16.9%抗核抗体阳性,平均随访106±50个月,无一例存在组织学自身免疫性肝炎或随访期间发展为自身免疫性肝炎。尽管抗核抗体阳性组基线非酒精性脂肪性肝炎患病率更高,但肝脏相关事件、肝细胞癌、心血管事件、肝外恶性肿瘤及总生存率与抗核抗体阴性组相似。

要点

  • 923例活检证实的非酒精性脂肪性肝病患者中16.9%抗核抗体阳性,平均随访106±50个月。
  • 抗核抗体阳性组基线非酒精性脂肪性肝炎患病率更高,但长期结局与阴性组相似。
  • 排除自身免疫性肝炎后,抗核抗体存在不影响非酒精性脂肪性肝病患者的长期结局和生存。

核心结论

  • 排除自身免疫性肝炎后,非酒精性脂肪性肝病患者中抗核抗体的存在不影响长期结局和生存。

研究设计与样本

  • 对923例经活检证实的非酒精性脂肪性肝病患者进行纵向研究,平均随访106±50个月。

主要发现

  • 923例经活检证实的非酒精性脂肪性肝病患者中16.9%抗核抗体阳性,无一例有组织学自身免疫性肝炎或随访期间发展为自身免疫性肝炎。
  • 抗核抗体阳性组基线非酒精性脂肪性肝炎患病率更高。
  • 抗核抗体阳性组肝脏相关事件、肝细胞癌、心血管事件、肝外恶性肿瘤及总生存率与抗核抗体阴性组相似。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: We investigated the longitudinal impact of antinuclear antibody (ANA) on clinical outcomes and survival in nonalcoholic fatty liver disease (NAFLD). METHODS: ANA were found in 16.9% of 923 biopsy-proven NAFLD patients, but none of them had histologic autoimmune hepatitis (AIH) or developed AIH after a mean follow-up of 106±50 months. RESULTS: Although ANA-positive cases had a higher prevalence of nonalcoholic steatohepatitis at baseline, the occurrence of liver-related events, hepatocellula carcinoma, cardiovascular events, extrahepatic malignancy, and overall survival were similar to ANA-negative. DISCUSSION: Once AIH has been ruled out, the long-term outcomes and survival are unaffected by the presence of ANA in patients with NAFLD.

来源:Am J Gastroenterol,查看原文。版权归原作者所有。

引用

  1. Younes R, Govaere O, Petta S, et al. Presence of Serum Antinuclear Antibodies Does Not Impact Long-Term Outcomes in Nonalcoholic Fatty Liver Disease. Am J Gastroenterol. 2020. PMID: 32453041. doi:10.14309/ajg.0000000000000676

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。